Takeda

Takeda Ventures, established in 2001, is the venture capital arm of Takeda Pharmaceutical Company Limited. Based in Cambridge, Massachusetts, with additional offices in San Diego, California, and globally, the firm specializes in direct and fund-of-fund investments, focusing on seed to mid-stage biotechnology and pharmaceutical companies. Takeda Ventures invests in therapeutics, including cardiovascular, inflammatory, metabolic, and oncological diseases, as well as regenerative medicines and novel technologies like RNA and DNA modulation. It typically invests between $0.25 million to $5 million, preferring minority stakes and board observer roles, and co-invests with other venture capital firms. Additionally, Takeda Ventures facilitates preclinical therapeutic discovery alliances and invests in digital health companies that improve patient outcomes and care delivery.

Jiaping Gu

Partner

Suzie Yoon

Investment Principal

182 past transactions

Daily Table

Grant in 2025
Daily Table is a non-profit grocery food store.

Harness Therapeutics

Venture Round in 2025
Harness Therapeutics is a private biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®. This innovative technology allows for the precise upregulation of protein expression, providing a unique mechanism of action for challenging diseases. By significantly expanding the druggable proteome, Harness Therapeutics aims to address conditions that have been difficult to treat with traditional small molecules, biologics, or gene therapies. The company's primary focus is on central nervous system and ophthalmologic disorders, although the potential applications of its platform extend across various therapeutic areas. Harness Therapeutics is committed to meeting unmet medical needs by creating differentiated products that enhance the translation of important, validated neurodegenerative targets.

Degron Therapeutics

Series A in 2025
Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Be Biopharma

Series C in 2025
Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

Be Biopharma

Venture Round in 2024
Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

Oshi Health

Series C in 2024
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.

Bulungula Incubator

Grant in 2024
Bulungula Incubator is an NPO that aims to sustainably end poverty in a generation while enhancing community life and cohesiveness.

Seed Global Health

Grant in 2024
Seed Global Health is an organization dedicated to improving health education and delivery in regions experiencing significant shortages of healthcare professionals. By partnering with countries in need, it aims to address long-term human resource challenges in healthcare. The organization provides experienced health professionals, who collaborate with local medical and nursing faculty to enhance training and educational programs. Additionally, Seed Global Health offers support in site selection, applicant recruitment, orientation, training, and ongoing field support. Its initiatives are designed to empower healthcare professionals to become leaders within their health systems, fostering advocacy for improved health outcomes through a sustainable, positive feedback loop.

VillageReach

Grant in 2024
VillageReach is an international NGO headquartered in Seattle, WA with field offices located in Malawi and Mozambique, Africa. Through collaboration with public and private sector partners, VillageReach seeks to increase access to quality healthcare for the world most underserved communities, bringing life-saving innovations to scale and sustainability. VillageReach develops, tests and implements solutions that uniquely address barriers at the lower levels or last mile of healthcare delivery in low-resource communities including medicine availability, human resource constraints, data visibility and lack of infrastructure.

Population Services International

Grant in 2024
PSI provides life-saving information, products, and services to tackle some of the world’s most pressing health problems so that people can lead healthier, happier, and more productive lives.

Reach Out Cameroon

Grant in 2024
Reach Out Cameroon is a non profit organisation aim is to improve the lives of the most vulnerable people using a community-centred approach.

Ascentage Pharma

Post in 2024
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Nabla Bio

Series A in 2024
Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

ISHI Health

Seed Round in 2024
ISHI Health is a technology company specializing in AI-driven virtual clinics for personalized care of heart failure and cardiometabolic patients. It provides an ecosystem of cardiac devices, continuous monitoring, educational resources, and patient empowerment tools, aiming to enhance patient convenience and clinical care team efficiency.

Maia Oncology

Seed Round in 2023
Maia Oncology is an onco-primary care clinic dedicated to supporting cancer patients and survivors. It operates a virtual cancer care coordination platform that offers comprehensive primary care tailored to the unique needs of this population. The platform is designed to track various patient outcomes, including hospitalizations, emergency room visits, and the onset of new comorbidities along with their severity. By providing this level of care, Maia Oncology aims to help patients effectively manage the toxicities and long-term complications associated with cancer treatment, enhancing their overall healthcare experience.

EvolveImmune Therapeutics

Venture Round in 2023
EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Crescendo Biologics

Venture Round in 2023
Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

Larkspur Biosciences

Series A in 2023
Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at enhancing cancer treatment. The company focuses on understanding how tumors manipulate the immune system and seeks to address these challenges by targeting specific molecular characteristics of patient populations. Larkspur's innovative approach is designed to foster a robust and sustained immune response, particularly in colorectal cancer, while also exploring applications for other cancers. By aligning its therapies with the unique molecular profiles of tumors, Larkspur aims to improve treatment outcomes for patients facing the complexities of cancer.

OncoResponse

Venture Round in 2023
OncoResponse Inc. is an immuno-oncology biotechnology company based in Houston, Texas, focused on developing innovative cancer therapies. The company utilizes a proprietary human antibody platform to identify fully human monoclonal antibodies targeting immuno-oncology pathways. By probing the adaptive immune systems of cancer patients who have shown exceptional responses to checkpoint inhibitors, OncoResponse aims to discover novel therapeutic antibodies. Its research emphasizes addressing immunosuppressive myeloid biology and enhancing immune activation, with the goal of transforming cold tumors into hot tumors that are more responsive to treatment. Through its advanced antibody pipeline, OncoResponse is dedicated to providing effective solutions for cancer treatment.

Oshi Health

Series B in 2023
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.

Atlanta Community Food Bank

Grant in 2023
Atlanta Community Food Bank serves food pantries, community kitchens, childcare centers, night shelters, and senior centers. The donors are manufacturers, wholesalers, retailers, brokers, restaurants, food drives, farmers, and individuals.

Martha’s Table

Grant in 2023
Marthas Table is a provider of healthy food and education for children of all ages.

Food For Free

Grant in 2023
Food For Free improves access to healthy food through establishing innovative programming and partnerships to overcome barriers and strengthen the community food system.

Red Sox Foundation

Grant in 2023
Red Sox Foundation is a Red Sox Nation power that improves health, educational, and recreational opportunities for kids, families, veterans, and communities in need. As part of their commitment to creating a good influence in their communities, Boston Red Sox Owner John Henry, Chairman Tom Werner, President/CEO Emeritus Larry Lucchino, and the team's partners formed and supported the Red Sox Foundation immediately after assuming ownership.

Project Scientist

Grant in 2023
The only focused effort of its kind, Project Scientist was developed to offer girls the essential support unique to each stage of a future scientists' life serving girls/women ages 4 to PhD age. Through extensive research on current trends and practices has built a robust & focused, three-phase, program pipeline to serve as a national model for advancing girls and women, of all ages, in their STEM interests and passions.

American Forests

Grant in 2023
American Forests offers services to restore threatened forest ecosystems and inspire people to value and protect urban and wildland forests. Their projects have restored hundreds of thousands of acres of wildlife habitat, protected vital watersheds, and sequestered millions of tons of greenhouse gases. They are advocates for expanding urban tree canopy and green space, and a key funder of urban forest initiatives that have transformed communities across the country.

Out Teach

Grant in 2023
Out Teach provides professional development for elementary school teachers.

Georgia Organics

Grant in 2023
Georgia Organics invests in organic farmers and community allies to cultivate a resilient, local food movement.

Breakthrough Greater Boston

Grant in 2023
Breakthrough Greater Boston transforms urban education for students and teachers through its unique Students Teaching Students model. Through six years of intensive, tuition-free out-of-school-time programming for traditionally underserved middle and high school students.

Greater Chicago Food Depository

Grant in 2023
Greater Chicago Food Depository they programs includes food pantries, soup kitchens, and shelters,

Common Threads

Grant in 2023
Common Threads offers psychotherapy, occupational therapy, and alternative school placement. Their purpose is to empower people with autism, mental health issues, and sensory challenges by providing them and their families with real assistance. They achieve this by providing a range of evidence-based, personalized therapeutic and educational programmes that are tailored to an individual's strengths, needs, and aspirations.

Boston Community Pediatrics

Grant in 2023
Boston Community Pediatrics is the first nonprofit private pediatric practice bringing equity to pediatric healthcare in Boston. BCP is a new model of innovative pediatric healthcare that addresses the social determinants of health within a relationship-driven framework.

American Red Cross

Grant in 2023
The American Red Cross (ARC), established in 1881 by Clara Barton, is a humanitarian organization dedicated to providing emergency assistance, disaster relief, and education across the United States. As the U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies, it plays a crucial role in disaster response and public safety. The ARC is the largest supplier of blood products in the country, collecting and processing around 40 percent of the nation's blood supply for distribution to approximately 2,600 hospitals and transfusion centers. The organization ensures the safety of the blood supply through rigorous testing and research, having been a pioneer in developing testing methods for various infectious diseases. Additionally, the ARC operates a nationwide hemovigilance program that monitors donor and patient reactions to improve blood product quality. Headquartered in Washington, D.C., the American Red Cross also collaborates with key committees and regulatory bodies, such as the U.S. Food and Drug Administration, to enhance safety standards in blood services.

Urban Farming Institute of Boston

Grant in 2023
Urban Farming Institute is a learning facility offering integrative farming methods designed to improve indoor farming operations. It combines tested, patented technologies with expert support on a global scale, assisting urban farmers in the process of vertical farming and streamlining processes linked to indoor horticulture. To get people involved in growing food and creating a healthy community, it has as its aim to create and promote urban farming.

Acumen

Grant in 2023
Acumen is a nonprofit organization established in 2001 and based in New York City, with additional offices in Mumbai, Nairobi, Karachi, and Accra. The organization is dedicated to poverty eradication by raising charitable funds to invest in early-stage companies that provide essential services such as clean energy, healthcare, education, agricultural inputs, formal housing, and safe drinking water to low-income communities. Acumen has made significant investments totaling $128 million in 128 companies across 14 countries, impacting the lives of over 308 million individuals. The organization collaborates with notable partners, including the Rockefeller Foundation, the Bill & Melinda Gates Foundation, and Google.org, to address critical challenges faced by underserved populations.

Mamas Kitchen

Grant in 2023
Mama's Kitchen aims to offer nutritional assistance to San Diego individuals at risk of undernourishment because of serious conditions like HIV, cancer, congestive heart failure, type 2 diabetes, and chronic renal disease.

San Diego River Park Foundation

Grant in 2023
San Diego River Park Foundation is a nonprofit organization created in 2001 to improve the future of the historic San Diego River, as well as the residents of San Diego and its visitors.

Cerevance

Series B in 2023
Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Ensoma

Series B in 2023
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Nimbus Lakshmi

Acquisition in 2022
Nimbus Lakshmi operates as a wholly-owned subsidiary of Nimbus Therapeutics and offers tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858, an orally administered, selective allosteric inhibitor of TYK2, is currently undergoing assessment for its potential in treating various autoimmune diseases, following promising Phase 2b outcomes in psoriasis.

Enzyre

Series A in 2022
Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care through point-of-care solutions. The company specializes in ambulant diagnostic devices that facilitate blood coagulation testing, allowing patients to perform up to twelve different reactions using a small volume of blood. This technology is designed to empower patients to conduct tests in various settings, including at home, while traveling, or in critical care environments, all without the need for traditional laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve quality of life while maintaining cost-effectiveness in healthcare.

Zelluna Immunotherapy

Venture Round in 2022
Zelluna Immunotherapy AS is a Norwegian biopharmaceutical company founded in 2016, dedicated to developing T-cell receptor (TCR) therapies targeting cancer antigens. Based in Oslo, the company aims to revolutionize cancer treatment by creating TCR-based immunotherapies with the potential to address a diverse array of cancer types. Zelluna's core asset consists of a collection of TCRs isolated from patients who achieved long-term survival after participating in peptide-based cancer vaccine trials. The company currently has multiple TCRs in various stages of development, focusing on guiding Natural Killer (NK) cells to elicit safe and effective cancer responses. Zelluna is affiliated with the Oslo Cancer Cluster, a network that includes stakeholders from the biotechnology industry, government, patient organizations, and research institutions, and operates within the Oslo Cancer Cluster Innovation Park, adjacent to the Norwegian Radium Hospital/Oslo University Hospital.

Code Biotherapeutics

Series A in 2022
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Be Biopharma

Series B in 2022
Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

Koneksa

Series C in 2022
Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Crohn's and Colitis Canada

Grant in 2022
Crohn's and Colitis Canada is a charitable group run entirely by volunteers dedicated to curing Crohn's disease and ulcerative colitis and enhancing the lives of children and adults who are affected by these conditions. Through research, patient programs, advocacy, and awareness, they are altering the lives of people with Crohn's or colitis. They lay the foundation for new and more effective treatments while also resulting in significant advances in the fields of genetics, gut microbes, inflammation, and cell repair.

Adaptate Biotherapeutics

Acquisition in 2022
Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Ambys Medicines

Series A in 2021
Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

Integra Therapeutics

Seed Round in 2021
Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

Aptihealth

Series B in 2021
Aptihealth is a behavioral health engagement company focused on enhancing the quality of behavioral healthcare, particularly for underserved populations. It has developed a technology-driven platform that integrates physical and behavioral healthcare through a comprehensive approach. This platform connects medical providers, behavioral health specialists, and patients, utilizing proprietary screening, assessment, and treatment management protocols. By offering personalized care delivery services, Aptihealth aims to streamline the care process and improve patient outcomes. Its digital solution facilitates virtual, integrated care, enabling patients to achieve better mental health more quickly and maintain their well-being over time.

Cardurion Pharmaceuticals

Venture Round in 2021
Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Egle Therapeutics

Series A in 2021
Egle Therapeutics SAS is a biotechnology company founded in 2020 and based in Paris, France. The company specializes in developing immunotherapies aimed at targeting immune suppressor regulatory T-cells (Tregs) to address oncology and autoimmune diseases. Egle Therapeutics is focused on its proprietary pipeline, which includes a series of computationally designed IL-2 variants designed to modulate Tregs by either engaging or disengaging them from tumor environments. Through its innovative approach to Treg modulation, the company aims to enable healthcare professionals to develop new therapies that effectively target these immune suppressor cells, potentially transforming treatment options for cancer and other diseases.

Oshi Health

Series A in 2021
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.

Tele911

Venture Round in 2021
Tele911 is a technology company that partners with Emergency Medical Services (EMS) agencies. It offers Tele911 Virtual Visit, an integrated telemedicine platform designed to care for stable patients remotely. This service aims to reduce unnecessary ambulance transports to hospitals, thereby saving resources and lowering healthcare system costs while maintaining high-quality patient care.

Turnstone Biologics

Series D in 2021
Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Harness Therapeutics

Seed Round in 2021
Harness Therapeutics is a private biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®. This innovative technology allows for the precise upregulation of protein expression, providing a unique mechanism of action for challenging diseases. By significantly expanding the druggable proteome, Harness Therapeutics aims to address conditions that have been difficult to treat with traditional small molecules, biologics, or gene therapies. The company's primary focus is on central nervous system and ophthalmologic disorders, although the potential applications of its platform extend across various therapeutic areas. Harness Therapeutics is committed to meeting unmet medical needs by creating differentiated products that enhance the translation of important, validated neurodegenerative targets.

BridGene Biosciences

Series A in 2021
BridGene Biosciences is a biotechnology company focused on discovering and developing innovative small molecules aimed at traditionally untreatable targets. By utilizing advanced chemoproteomic technology, the company facilitates proteome-wide screening in live cells, which allows for the identification of highly selective small molecules. BridGene employs a combination of covalent chemistry, chemical proteomics, and quantitative mass spectrometry to create therapeutics and covalent small-molecule inhibitors. This approach positions BridGene to enable the healthcare industry to uncover new drug targets and develop effective treatments for challenging conditions.

Code Biotherapeutics

Seed Round in 2021
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Adaptate Biotherapeutics

Series A in 2021
Adaptate Biotherapeutics is a London-based biotherapeutics company founded in 2019 by Adrian Hayday. The company specializes in developing antibody-based therapies aimed at modulating gamma delta T cells in situ. By leveraging innovative technologies, Adaptate focuses on creating immunotherapies that target cancer and autoimmune diseases. Its approach has the potential to significantly influence treatment options for patients with these conditions, providing access to effective and novel therapeutic modalities.

Arcellx

Series C in 2021
Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies, particularly in the realm of cell therapy, for patients with cancer and other serious diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Arcellx's lead product candidate, CART-ddBCMA, is currently being investigated in a Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. This therapy has received several designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is progressing its dosable and controllable CAR-T therapy, known as ARC-SparX, through two clinical programs targeting relapsed or refractory multiple myeloma and acute myeloid leukemia. Through these efforts, Arcellx seeks to contribute significantly to the advancement of cell therapy in modern medicine.

StrideBio

Series B in 2021
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Maverick Therapeutics

Acquisition in 2021
Maverick Therapeutics, Inc. is a biotechnology company based in Brisbane, California, that specializes in developing T-cell engagement therapeutics aimed at treating solid tumor cancers. Founded in 2016, the company focuses on creating innovative immunotherapies that enhance safety and efficacy for patients. Its proprietary platform, COBRA™, is recognized as a leading bispecific T-cell engaging technology, engineered to target solid tumors with high specificity and potency. This novel platform addresses toxicity challenges associated with cancer treatments by remaining inactive upon administration and becoming fully active within the tumor microenvironment, thereby optimizing T-cell redirection therapy. Through its advancements, Maverick Therapeutics aims to improve patient outcomes and facilitate more effective cancer care.

Presage Biosciences

Convertible Note in 2021
Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Xilio Therapeutics

Series C in 2021
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Ensoma

Series A in 2021
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Aspen RxHealth

Series B in 2021
Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists with patients based on various social and clinical criteria, including language and medication regimens. The platform enables health plans and providers to efficiently link their patients to a community of pharmacists who can offer specialized clinical services, ranging from comprehensive medication reviews to targeted interventions. By optimizing communication and simplifying processes, Aspen RxHealth aims to improve patient outcomes and enhance the delivery of pharmaceutical care.

Catamaran Bio

Series A in 2020
Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Bridge Medicines

Funding Round in 2020
Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Be Biopharma

Series A in 2020
Be Biopharma, Inc. is a biopharmaceutical company focused on developing therapeutics derived from engineered B-cells in the immune system. Founded in 2020 and based in Cambridge, Massachusetts, Be Biopharma aims to address the limitations of existing cell and gene therapies, such as the need for chemotherapy prior to treatment and the challenges of providing multiple doses. The company employs precision genome editing to create durable and effective cell therapies, targeting a range of diseases, including cancer, autoimmune disorders, and infectious diseases. By enhancing the functionality of B-cell medicines, Be Biopharma seeks to improve treatment outcomes for conditions like Hemophilia B and other serious health issues.

xFOREST Therapeutics

Seed Round in 2020
xFOREST Therapeutics is a biotechnology company focused on advancing drug discovery through its innovative platform for ribonucleic acid (RNA) targeting drugs. The company specializes in integrating massively parallel biochemical analysis systems that evaluate diverse RNA structures, irrespective of their source organ, species, or virus. This approach allows xFOREST to accelerate the identification and development of impactful therapeutics that selectively target RNA, addressing significant challenges in the RNA-targeted drug space. By leveraging in silico analysis pipelines alongside its biochemical technologies, xFOREST aims to provide critical solutions for patients in need of effective RNA-based treatments.

Oshi Health

Seed Round in 2020
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.

Palleon Pharmaceuticals

Series B in 2020
Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

ImmPACT Bio

Series A in 2020
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

VelosBio

Series B in 2020
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Enterome

Series E in 2020
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Amwell

Series C in 2020
Amwell is a telehealth platform based in the United States that facilitates the digital delivery of healthcare services. Founded in 2006 and headquartered in Boston, the company connects providers, insurers, patients, and innovators to enhance access to affordable, high-quality care. Amwell offers a comprehensive platform designed to address a wide range of telehealth needs, including urgent, acute, and post-acute care, as well as chronic care management and healthy living. With extensive experience in the field, Amwell supports over 240 health systems, which encompass 2,000 hospitals, and collaborates with 55 health plan partners, reaching more than 150 million individuals through over 36,000 employers. The platform provides both on-demand and scheduled consultations, enabling diverse care models that range from primary and urgent care to specialized services such as telestroke and telepsychiatry.

Cerevance

Series B in 2020
Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Redpin Therapeutics

Series A in 2020
Redpin Therapeutics, Inc. is a preclinical stage gene therapy company founded in 2017 and based in New York, New York. The company specializes in developing a proprietary chemogenetics platform for targeted cell therapies aimed at addressing intractable diseases of the nervous system. Redpin's innovative approach utilizes ion channels as neuromodulation tools, allowing for selective activation or inhibition of disease-causing neurons while preserving normal functioning cells. By controlling these neuronal circuits, Redpin enables physicians to precisely target dysfunctional neural activity associated with specific conditions. The company's technology integrates principles from synthetic biology, gene therapy, and traditional pharmacotherapy to advance its mission of addressing complex neurological disorders.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

PvP Biologics

Acquisition in 2020
PVP Biologics, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapeutic products for celiac disease. Established in 2015, the company specializes in creating an oral enzyme designed to break down immuno-reactive components of gluten in the stomach. This approach aims to alleviate the painful symptoms and intestinal damage caused by accidental gluten ingestion in individuals with celiac disease. By advancing this product candidate, PVP Biologics seeks to significantly reduce the burden of living with this condition and improve the quality of life for those affected. As of early 2020, PVP Biologics operates as a subsidiary of Takeda Pharmaceutical Company Limited.

Emendo Biotherapeutics

Series B in 2020
Emendo Biotherapeutics is a biotechnology company focused on advancing genome editing technologies to develop genetic medicines. Established by a team of experts with backgrounds in protein engineering and DNA repair from prestigious institutions, Emendo aims to tackle the challenges associated with gene therapy. By innovating and transforming existing tools, the company seeks to address diseases and disorders that are presently deemed untreatable. Emendo's approach fuses diverse scientific disciplines with creative problem-solving, enabling the development of advanced gene editing solutions that enhance the efficacy of gene therapy and expand its potential applications. Through this commitment to pushing the boundaries of science, Emendo Biotherapeutics strives to fulfill the promise of gene editing for improved patient outcomes.

EvolveImmune Therapeutics

Venture Round in 2020
EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Harness Therapeutics

Seed Round in 2020
Harness Therapeutics is a private biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®. This innovative technology allows for the precise upregulation of protein expression, providing a unique mechanism of action for challenging diseases. By significantly expanding the druggable proteome, Harness Therapeutics aims to address conditions that have been difficult to treat with traditional small molecules, biologics, or gene therapies. The company's primary focus is on central nervous system and ophthalmologic disorders, although the potential applications of its platform extend across various therapeutic areas. Harness Therapeutics is committed to meeting unmet medical needs by creating differentiated products that enhance the translation of important, validated neurodegenerative targets.

Turnstone Biologics

Corporate Round in 2019
Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Oshi Health

Pre Seed Round in 2019
Oshi Health is a virtual-first gastroenterology clinic focused on diagnosing, treating, and remotely monitoring digestive conditions. The company employs an integrated care team comprising gastroenterologists, GI-specialized nurse practitioners, registered dietitians, behavioral psychologists, and health coaches. This multidisciplinary approach allows patients to identify the root causes of their symptoms and develop personalized care plans that incorporate medication, dietary changes, and gut-brain behavioral therapy. Oshi Health aims to enhance access to digestive health care, improve patient experiences, and achieve better clinical outcomes, ultimately helping patients gain lasting control over their symptoms and improve their quality of life.

Avidity Biosciences

Series C in 2019
Avidity Biosciences, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of oligonucleotide-based therapies, particularly through its innovative Antibody Oligonucleotide Conjugates (AOC) platform. This technology aims to address the limitations of traditional oligonucleotide therapies by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide treatments. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disease. In addition to this, the company is advancing multiple programs focused on muscle-related conditions, including muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Furthermore, Avidity is expanding its research to include immune and other cell types, positioning itself at the forefront of biopharmaceutical innovation for serious diseases.

ProteKt Therapeutics

Venture Round in 2019
ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR, targeting neurodegenerative and neuroinflammatory diseases. The company utilizes unique computational methods to develop a series of novel and selective molecules, which are validated through clinically relevant assays. This approach aims to address issues such as memory consolidation impairment and enhance long-term memory in patients. In 2019, ProteKt Therapeutics graduated from the FutuRx accelerator and subsequently raised $4 million in a pre-A funding round to support its innovative research and development efforts.

Arcellx

Series B in 2019
Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies, particularly in the realm of cell therapy, for patients with cancer and other serious diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Arcellx's lead product candidate, CART-ddBCMA, is currently being investigated in a Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. This therapy has received several designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is progressing its dosable and controllable CAR-T therapy, known as ARC-SparX, through two clinical programs targeting relapsed or refractory multiple myeloma and acute myeloid leukemia. Through these efforts, Arcellx seeks to contribute significantly to the advancement of cell therapy in modern medicine.

Phathom Pharmaceuticals

Venture Round in 2019
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Hookipa Pharma

Series D in 2019
Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

BiomX

Series B in 2019
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Ribon Therapeutics

Series B in 2019
Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Axcelead

Seed Round in 2018
Axcelead Drug Discovery Partners specializes in providing comprehensive drug discovery services that connect foundational scientific research to clinical development. The company focuses on early-stage drug discovery, offering integrated solutions that span from exploratory research to the optimization of candidate compounds. With a commitment to scientific excellence, Axcelead employs state-of-the-art facilities that are GLP-accredited, ensuring high-quality standards in its operations. By leveraging its expertise and advanced technologies, the company aims to facilitate clients' access to essential drug-discovery capabilities, thereby enhancing the overall efficiency of the drug development process.

Avidity Biosciences

Series B in 2018
Avidity Biosciences, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of oligonucleotide-based therapies, particularly through its innovative Antibody Oligonucleotide Conjugates (AOC) platform. This technology aims to address the limitations of traditional oligonucleotide therapies by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide treatments. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disease. In addition to this, the company is advancing multiple programs focused on muscle-related conditions, including muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Furthermore, Avidity is expanding its research to include immune and other cell types, positioning itself at the forefront of biopharmaceutical innovation for serious diseases.

Bsense Bio Therapeutics

Seed Round in 2018
Bsense Bio Therapeutics specializes in the development of small molecules aimed at treating disorders associated with sensory hyperexcitability. The company has pioneered a novel approach that targets multiple mechanisms related to hyperexcitability through the use of a single compound. This strategy focuses on the interaction with two key types of ion channels: a ligand-gated cation channel and a voltage-gated potassium channel. By doing so, Bsense Bio Therapeutics seeks to enhance both the efficacy and safety of treatments for clinicians and patients affected by these conditions.

VelosBio

Series A in 2018
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Ramino Bio

Seed Round in 2018
Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.